AI Article Synopsis

Article Abstract

Autoimmune disease is a critical health concern, whose etiology remains enigmatic. We hypothesized that immune responses to somatically mutated self proteins could have a role in the development of autoimmune disease. IFN-γ secretion by T cells stimulated with mitochondrial peptides encoded by published mitochondrial DNA was monitored to test the hypothesis. Human peripheral blood mononuclear cells (PBMCs) of healthy controls and autoimmune patients were assessed for their responses to the self peptides and mutated-self peptides differing from self by one amino acid. None of the self peptides but some of the mutated-self peptides elicited an immune response in healthy controls. In some autoimmune patients, PBMCs responded not only to some of the mutated-self peptides, but also to some of the self peptides, suggesting that there is a breach of self-tolerance in these patients. Although PBMCs from healthy controls failed to respond to self peptides when stimulated with self, the mutated-self peptide could elicit a response to the self peptide upon re-stimulation in vitro, suggesting that priming with mutated-self peptides elicits a cross-reactive response with self. The data raise the possibility that DNA somatic mutations are one of the events that trigger and/or sustain T cell responses in autoimmune diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humimm.2014.06.012DOI Listing

Publication Analysis

Top Keywords

mutated-self peptides
20
healthy controls
12
peptides
10
mitochondrial dna
8
dna somatic
8
somatic mutations
8
autoimmune disease
8
pbmcs healthy
8
controls autoimmune
8
autoimmune patients
8

Similar Publications

T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.

Front Immunol

April 2022

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Rockville, MD, United States.

In cancer, non-synonymous DNA base changes alter protein sequence and produce neoantigens that are detected by the immune system. For immune detection, neoantigens must first be presented on class I or II human leukocyte antigens (HLA) followed by recognition by peptide-specific receptors, exemplified by the T-cell receptor (TCR). Detection of neoantigens represents a unique challenge to the immune system due to their high similarity with endogenous 'self' proteins.

View Article and Find Full Text PDF

Tumor-specific neoantigens are mutated self-peptides presented by tumor cell major histocompatibility complex (MHC) molecules and are necessary to elicit host's anti-cancer cytotoxic T cell responses. It could be specifically recognized by neoantigen-specific T cell receptors (TCRs). However, current wet-lab assays for identifying peptide MHC binding are too expensive and time-consuming to meet the clinical needs.

View Article and Find Full Text PDF

Generation of affinity ranged antigen-expressing tumor cell lines.

Methods Enzymol

December 2020

Department of Oncology UNIL-CHUV, Faculty of Biology and Medicine, University of Lausanne, Epalinges, Switzerland. Electronic address:

The interaction strength between CD8 T cells' TCR and cognate peptide-MHC (pMHC) impacts on the CD8 T cell response against pathogens and tumors (Martinez-Usatorre, Donda, Zehn, & Romero, 2018; Zehn, Lee, & Bevan, 2009). CD8 T cell responses against tumors are characterized by the presence of low affinity CD8 T cells specific for nonmutated tumor associated self-antigens (TAA) and potentially high affinity tumor specific CD8 T cells recognizing mutated self-antigens (Gros et al., 2016; Kvistborg et al.

View Article and Find Full Text PDF

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.

Cancer Immunol Immunother

October 2019

Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.

Article Synopsis
  • Preclinical and clinical studies indicate that cancer treatment with antitumor antibodies generates a specific immune response, particularly involving CD4 T cells.
  • This research identifies 21 T cell epitopes derived from the human CD20 protein, which are restricted by various HLA types and can stimulate T cell activity in both healthy individuals and lymphoma patients.
  • These identified CD20-derived peptides have potential as therapeutic agents to enhance or track T cell responses in patients receiving anti-CD20 treatments like rituximab.
View Article and Find Full Text PDF

The T cell receptor (TCR) initiates the elimination of pathogens and tumors by T cells. To avoid damage to the host, the receptor must be capable of discriminating between wild-type and mutated self and nonself peptide ligands presented by host cells. Exactly how the TCR does this is unknown.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!